Citation Tools
PDFClinical/translational cancer immunotherapy
Original research
CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation